340 related articles for article (PubMed ID: 9725246)
1. Subcellular site of expression and route of vaccination influence pulmonary eosinophilia following respiratory syncytial virus challenge in BALB/c mice sensitized to the attachment G protein.
Bembridge GP; Garcia-Beato R; López JA; Melero JA; Taylor G
J Immunol; 1998 Sep; 161(5):2473-80. PubMed ID: 9725246
[TBL] [Abstract][Full Text] [Related]
2. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.
Li X; Sambhara S; Li CX; Ettorre L; Switzer I; Cates G; James O; Parrington M; Oomen R; Du RP; Klein M
Virology; 2000 Mar; 269(1):54-65. PubMed ID: 10725198
[TBL] [Abstract][Full Text] [Related]
3. Priming with a secreted form of the fusion protein of respiratory syncytial virus (RSV) promotes interleukin-4 (IL-4) and IL-5 production but not pulmonary eosinophilia following RSV challenge.
Bembridge GP; Lopez JA; Bustos R; Melero JA; Cook R; Mason H; Taylor G
J Virol; 1999 Dec; 73(12):10086-94. PubMed ID: 10559323
[TBL] [Abstract][Full Text] [Related]
4. Host genetic determinants of vaccine-induced eosinophilia during respiratory syncytial virus infection.
Hussell T; Georgiou A; Sparer TE; Matthews S; Pala P; Openshaw PJ
J Immunol; 1998 Dec; 161(11):6215-22. PubMed ID: 9834108
[TBL] [Abstract][Full Text] [Related]
5. Immune responses to the nonglycosylated ectodomain of respiratory syncytial virus attachment glycoprotein mediate pulmonary eosinophilia in inbred strains of mice with different MHC haplotypes.
Hancock GE; Tebbey PW; Scheuer CA; Pryharski KS; Heers KM; LaPierre NA
J Med Virol; 2003 Jun; 70(2):301-8. PubMed ID: 12696122
[TBL] [Abstract][Full Text] [Related]
6. Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection.
Johnson TR; Graham BS
Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S46-57. PubMed ID: 14730270
[TBL] [Abstract][Full Text] [Related]
7. Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection.
Srikiatkhachorn A; Braciale TJ
J Exp Med; 1997 Aug; 186(3):421-32. PubMed ID: 9236194
[TBL] [Abstract][Full Text] [Related]
8. Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology.
Cyr SL; Jones T; Stoica-Popescu I; Brewer A; Chabot S; Lussier M; Burt D; Ward BJ
Vaccine; 2007 Jul; 25(29):5378-89. PubMed ID: 17561317
[TBL] [Abstract][Full Text] [Related]
9. Abundant IFN-gamma production by local T cells in respiratory syncytial virus-induced eosinophilic lung disease.
Spender LC; Hussell T; Openshaw PJ
J Gen Virol; 1998 Jul; 79 ( Pt 7)():1751-8. PubMed ID: 9680139
[TBL] [Abstract][Full Text] [Related]
10. Murine host responses to respiratory syncytial virus (RSV) following intranasal administration of a Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine.
Huang Y; Cyr SL; Burt DS; Anderson R
J Clin Virol; 2009 Apr; 44(4):287-91. PubMed ID: 19233722
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic and functional characterization of T cell lines specific for individual respiratory syncytial virus proteins.
Alwan WH; Record FM; Openshaw PJ
J Immunol; 1993 Jun; 150(12):5211-8. PubMed ID: 8515055
[TBL] [Abstract][Full Text] [Related]
12. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment.
Power UF; Plotnicky-Gilquin H; Huss T; Robert A; Trudel M; Ståhl S; Uhlén M; Nguyen TN; Binz H
Virology; 1997 Apr; 230(2):155-66. PubMed ID: 9143271
[TBL] [Abstract][Full Text] [Related]
13. Expression of interleukin-4 by recombinant respiratory syncytial virus is associated with accelerated inflammation and a nonfunctional cytotoxic T-lymphocyte response following primary infection but not following challenge with wild-type virus.
Bukreyev A; Belyakov IM; Prince GA; Yim KC; Harris KK; Berzofsky JA; Collins PL
J Virol; 2005 Aug; 79(15):9515-26. PubMed ID: 16014914
[TBL] [Abstract][Full Text] [Related]
14. The effect of IL-12 treatment on vaccine-enhanced illness during infection with respiratory syncytial virus.
Openshaw PJ; Hussell T
Dev Biol Stand; 1998; 92():179-85. PubMed ID: 9554273
[TBL] [Abstract][Full Text] [Related]
15. Polylactide-co-glycolide (PLG) microparticles modify the immune response to DNA vaccination.
Helson R; Olszewska W; Singh M; Megede JZ; Melero JA; O'Hagan D; Openshaw PJ
Vaccine; 2008 Feb; 26(6):753-61. PubMed ID: 18191308
[TBL] [Abstract][Full Text] [Related]
16. CD8+ T cells control Th2-driven pathology during pulmonary respiratory syncytial virus infection.
Hussell T; Baldwin CJ; O'Garra A; Openshaw PJ
Eur J Immunol; 1997 Dec; 27(12):3341-9. PubMed ID: 9464822
[TBL] [Abstract][Full Text] [Related]
17. Recombinant vaccinia virus coexpressing the F protein of respiratory syncytial virus (RSV) and interleukin-4 (IL-4) does not inhibit the development of RSV-specific memory cytotoxic T lymphocytes, whereas priming is diminished in the presence of high levels of IL-2 or gamma interferon.
Bembridge GP; Lopez JA; Cook R; Melero JA; Taylor G
J Virol; 1998 May; 72(5):4080-7. PubMed ID: 9557697
[TBL] [Abstract][Full Text] [Related]
18. Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques.
Elliott MB; Chen T; Terio NB; Chong SY; Abdullah R; Luckay A; Egan MA; Boutilier LA; Melville K; Lerch RA; Long D; Eldridge JH; Parks CL; Udem SA; Hancock GE
Vaccine; 2007 Oct; 25(41):7132-44. PubMed ID: 17850933
[TBL] [Abstract][Full Text] [Related]
19. Efficient lung recruitment of respiratory syncytial virus-specific Th1 cells induced by recombinant bacillus Calmette-Guérin promotes virus clearance and protects from infection.
Cautivo KM; Bueno SM; Cortes CM; Wozniak A; Riedel CA; Kalergis AM
J Immunol; 2010 Dec; 185(12):7633-45. PubMed ID: 21084664
[TBL] [Abstract][Full Text] [Related]
20. IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge.
Johnson TR; Parker RA; Johnson JE; Graham BS
J Immunol; 2003 Feb; 170(4):2037-45. PubMed ID: 12574374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
